Fisetin occupies a distinct position in the longevity supplement landscape. It is not an NAD+ precursor, not a sirtuin activator, and not a methylation supporter. It is a senolytic — a compound that selectively clears senescent cells, the dysfunctional, non-dividing cells that accumulate with age and drive chronic inflammation throughout the body. Of all the natural compounds studied for senolytic activity, fisetin has generated the most scientific attention and has accumulated the strongest animal evidence. The human clinical trial picture is earlier-stage but actively developing, with several well-designed trials either recently completed or in progress. This guide covers what fisetin is, how senolytics work, what the evidence shows, and what to know if considering supplementation.
What Senescent Cells Are and Why Clearing Them Matters
To understand fisetin, it helps to understand the problem it targets. Cellular senescence is a biological state in which a cell permanently stops dividing but resists normal programmed cell death (apoptosis). Senescent cells emerge in response to DNA damage, oxidative stress, telomere shortening, and other insults — and in younger tissues they are rapidly cleared by the immune system. With age, both the accumulation rate and the clearance failure rate increase, causing senescent cells to build up in tissues throughout the body.
The problem is not merely that these cells are non-functional. Senescent cells actively harm their neighbors by secreting a cocktail of inflammatory cytokines, proteases, and signaling molecules called the senescence-associated secretory phenotype (SASP). The SASP promotes local tissue damage, spreads inflammatory signals systemically, and — in a particularly insidious mechanism — induces nearby healthy cells to become senescent themselves. This senescent cell accumulation and the resulting chronic inflammation are increasingly recognized as drivers of cardiovascular disease, neurodegeneration, metabolic dysfunction, frailty, and cancer progression. Our article on senescent cells and senolytics covers this biology in depth.
Senolytics work by exploiting a vulnerability of senescent cells: to survive despite carrying extensive DNA damage and metabolic dysfunction, they upregulate anti-apoptotic pathways that shield them from cell death signals. Senolytic compounds disrupt these shields, allowing the cell’s own apoptotic machinery to eliminate it. Importantly, senescent cells have different anti-apoptotic dependencies than healthy cells, which is why well-designed senolytics can selectively clear senescent cells while leaving healthy tissue intact.
What Fisetin Is and Where It Comes From
Fisetin is a flavonol — a subclass of flavonoids — found in a variety of fruits and vegetables. Strawberries are the richest known dietary source, containing approximately 160 micrograms of fisetin per gram. Other sources include apples, grapes, persimmons, onions, and cucumbers, all at considerably lower concentrations. The compound was first isolated from the smoke bush plant in 1833 and has been studied for antioxidant and anti-inflammatory properties since the early 2000s, though its senolytic activity became the focus of major research attention after 2018.
The disconnect between dietary and therapeutic doses is significant. A cup of strawberries contains roughly 0.16 mg of fisetin. The doses used in positive mouse studies, when converted to human-equivalent doses by standard body surface area scaling, translate to approximately 7 to 20 mg per kilogram of body weight — meaning a 70 kg person would need the rough equivalent of several thousand strawberries to match the animal doses. Dietary fisetin contributes to general antioxidant and anti-inflammatory status, but senolytic dosing requires supplementation.
The Animal Evidence: Among the Strongest for Any Natural Compound
The landmark study that established fisetin’s place in longevity research was published in EBioMedicine in 2018 by Yousefzadeh, Zhu, and colleagues at the Mayo Clinic. This study found that fisetin was the most potent senolytic among 10 flavonoids tested, selectively eliminating approximately 70% of senescent cells in tissue culture while leaving healthy cells unharmed. In aged mice (treated at 22 to 24 months of age, roughly equivalent to the human 70s or 80s), fisetin treatment reduced senescent cell burden in multiple tissues, reduced systemic SASP markers, improved physical function, and — notably — extended remaining lifespan by approximately 10%. This lifespan extension in already-old mice is among the more striking findings in the senolytic field, since it suggests the intervention can produce meaningful benefit even when started late in life.
More recent animal research has continued to strengthen the case. A 2025 study by Murray, Mahoney, and colleagues at the University of Colorado and the National Institute on Aging, published in Aging Cell, found that intermittent fisetin supplementation in aged mice improved grip strength and reduced frailty to a degree comparable to both genetic clearance of senescent cells and treatment with ABT-263 (Navitoclax), a synthetic senolytic pharmaceutical. This comparison to pharmaceutical and genetic interventions is significant — it suggests fisetin operates through the same fundamental biology as these more targeted approaches and achieves comparable functional outcomes in animals.
A 2025 preprint from the same University of Colorado group found that fisetin reversed age-related endothelial dysfunction — the impairment of blood vessel inner lining function that underlies cardiovascular aging — through a mechanism involving clearance of senescent cells and reduction of a SASP factor called CXCL12. Cardiovascular endothelial dysfunction is one of the most clinically relevant aging phenotypes, and reversal of it in old mice represents a functionally important finding.
What Human Clinical Trials Have Found
The honest position on fisetin’s human clinical evidence is that it is at an earlier stage than the animal data, with several important trials recently completed or still in progress. The most significant limitation is that no completed, published, large-scale human trial has yet demonstrated that fisetin clears senescent cells in human tissues — the primary endpoint that animal studies have established so clearly. This gap between animal and human evidence is a genuine limitation that distinguishes fisetin from NMN and NR, where NAD+-raising effects in humans are firmly established.
Early Human Safety and Feasibility Data
A 2019 pilot study (Kirkland, Tchkonia, and colleagues at the Mayo Clinic) tested fisetin supplementation in women with obesity — a population with elevated senescent cell burden — using 100 mg twice daily for two days. The study found the intervention to be safe and feasible, with no significant adverse effects, and reported some reduction in inflammatory markers. This was not designed to assess longevity or senolytic outcomes, but it established tolerability at this dose.
Two additional Mayo Clinic trials deserve attention. The COVID-FIS trial (NCT04537299), testing fisetin in older adults in nursing homes with COVID-19, completed in November 2024 and posted results in August 2025 — this is one of the first completed fisetin human trials with publicly available results, though published peer-reviewed analysis was not yet available at the time of writing. The COVID-FISETIN trial (NCT04476953) from Mayo Clinic tested fisetin to prevent inflammatory complications in COVID-19 patients and was still active as of late 2025.
The AFFIRM (Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women) phase 2 trial, the largest and most important fisetin trial currently underway, was still enrolling as of November 2025 with primary completion estimated in April 2026. When published, AFFIRM results will represent the most significant human evidence for fisetin’s senolytic and frailty-related effects to date. This site will cover those results when available.
Indirect Human Evidence
Beyond direct intervention trials, fisetin has been tested in two completed human trials with published results that provide more than safety data. A randomized controlled trial in stroke patients found that fisetin improved outcomes relative to standard care alone. A separate study found that fisetin reduced inflammatory markers in cancer patients undergoing treatment. Neither of these trials was designed to test senolytic mechanisms in healthy aging adults, but both support biological activity in humans and add to the safety evidence base.
The Bioavailability Challenge
Like resveratrol, fisetin faces a significant bioavailability limitation. It is poorly water-soluble and undergoes rapid first-pass metabolism in the liver, with only a small fraction of an oral dose reaching systemic circulation as intact fisetin. This creates a practical problem: the doses used in positive mouse experiments are high, and even supplemental doses may not achieve the tissue concentrations that produced the animal results.
Practical strategies to improve absorption include taking fisetin with a fat-containing food or meal, since its lipophilic nature means dietary fat aids incorporation into bile acid micelles for intestinal absorption, similar to resveratrol. Some commercial formulations include fats (MCT oil, for example) or absorption enhancers for this reason. Newer formulations using liposomal encapsulation or complexing with cyclodextrins have shown improved bioavailability in preclinical testing, though head-to-head human comparison data is limited. The standard practical recommendation is to take fisetin with a fat-containing food and to choose formulations with stated bioavailability enhancement over plain powder-in-capsule formats.
Dosage and Cycling: What Researchers Use
Fisetin dosing is less standardized than for NMN or NR, partly because the optimal human dosing protocol has not been established. Two general approaches are used: daily low-dose supplementation for general antioxidant and anti-inflammatory support, and intermittent higher-dose senolytic protocols.
For daily use, most commercial products provide 100 to 500 mg per day. This range is far below the 20 mg per kilogram body weight human-equivalent dose from the most compelling animal studies, but it is also the dose range with the most human safety documentation. For intermittent senolytic protocols, the approach used in the AFFIRM-LITE trial and adopted by many longevity practitioners involves 20 mg per kilogram body weight (roughly 1,000 to 1,500 mg for most adults) taken for two consecutive days per month. This “hit and run” intermittent approach is based on the biology of senolytics: since the goal is to clear an accumulated population of senescent cells rather than to maintain a constant drug level, periodic high doses may be more effective than continuous low doses. The intermittent approach also reduces any concerns about the systemic effects of continuously high fisetin exposure.
Whether a daily low-dose approach, an intermittent high-dose approach, or some combination produces the best outcomes in humans is not established by current clinical data. Until AFFIRM results are published, the choice between approaches involves applying the animal protocol logic to human use without definitive human validation.
Safety: What Is Known and What Remains Uncertain
The completed human safety data on fisetin at doses up to 200 mg per day over short periods is reassuring — no significant adverse effects have been documented in the available trials. At the higher intermittent doses used in senolytic protocols (1,000 mg or more for two-day courses), the published human safety record is thinner. Animal studies have not shown toxicity at equivalent doses, and fisetin has been consumed as a food component for as long as humans have eaten strawberries. The absence of long-term large-scale human supplementation trials means that complete characterization of safety remains to be established.
Several specific cautions apply. Most commercial fisetin supplements are derived from the smoke bush plant (Rhus succedanea) rather than from strawberries, which is a practical source consideration but not a safety concern for most people. Fisetin may interact with certain medications, including blood thinners and drugs metabolized by CYP3A4 enzymes, so anyone on regular medications should discuss fisetin supplementation with their physician. As with spermidine, the relationship between senolytics and cancer is nuanced — the evidence suggests senolytic activity is generally anti-tumorigenic, but people with active cancer should discuss use with their oncologist.
Fisetin in the Longevity Stack
Fisetin’s mechanism — senescent cell clearance — is distinct from and complementary to both the NAD+-sirtuin axis that NMN and NR address and the autophagy-induction pathway that spermidine activates. A multi-pathway longevity approach that includes NAD+ precursor support, autophagy support, and senolytic clearing addresses three of the most studied age-related cellular processes through independent mechanisms. This multi-layer rationale for combining NMN or NR, spermidine, and fisetin (alongside resveratrol for sirtuin activation) is the basis for what has become the standard advanced longevity stack among researchers and well-informed enthusiasts. Our advanced longevity stack guide covers how these compounds work together and how to sequence supplementation practically.
Fisetin is also frequently combined with quercetin, which operates through overlapping but somewhat complementary senolytic mechanisms and targets different subpopulations of senescent cells. The fisetin-quercetin combination is discussed in our quercetin guide.
Frequently Asked Questions About Fisetin
What Makes Fisetin Different From Quercetin as a Senolytic?
Both fisetin and quercetin are flavonoids with senolytic activity, and they are frequently combined in longevity stacks. The primary differences are potency and selectivity: fisetin was found to be more potent than quercetin in the 2018 Mayo Clinic screening study across the panel of flavonoids tested. They appear to target somewhat different populations of senescent cells through overlapping but distinct mechanisms. The combination of fisetin and quercetin is thought to provide broader senolytic coverage than either compound alone — which is why many senolytic products and protocols include both.
Is Fisetin From Strawberries Different From Supplement Fisetin?
Chemically, fisetin from strawberries and fisetin from supplement sources (typically derived from the smoke bush) is the same molecule. The practical difference is concentration: dietary sources provide milligram fractions of the doses used in research, while supplements provide concentrated, consistent doses. For general antioxidant support, dietary fisetin from a varied diet contributes meaningfully. For senolytic protocols that require higher doses, supplementation is the practical route. There is no known safety difference between dietary and supplemental sources of the molecule itself.
Should Fisetin Be Taken Daily or Intermittently?
Both protocols are used, with different rationales. Daily low doses (100 to 500 mg) address antioxidant, anti-inflammatory, and neuroprotective properties but likely do not achieve the tissue concentrations needed for meaningful senolytic clearance. Intermittent higher-dose protocols (approximately 20 mg per kilogram body weight for two consecutive days per month) are designed to clear accumulated senescent cell populations, following the “hit and run” logic that periodic high exposures are more effective for cell clearance than continuous low exposures. The intermittent senolytic approach is more aligned with the mechanism but has less human safety data. Some people combine both — a low daily dose for continuous support and periodic higher-dose protocols for senolytic effect.
How Long Before Fisetin Produces Noticeable Effects?
Unlike NMN or NR, where NAD+ blood levels rise within one to two weeks, fisetin’s primary longevity mechanism — clearing accumulated senescent cells — is a slower biological process. Animal studies typically run for months. Human trials have used periods of three months to a year. Subjective effects, if any are noticed, are unlikely to appear quickly. The appropriate expectation is that fisetin (particularly in an intermittent senolytic protocol) may improve long-term healthspan markers over months to years rather than producing noticeable short-term effects. This is one reason fisetin is most appropriately thought of as a long-horizon longevity investment rather than a supplement you take and feel within weeks.
Is the Human Evidence for Fisetin Strong Enough to Justify Supplementation?
This is a fair question, and the honest answer is that the human evidence is not yet at the level of NMN or NR in terms of replicated clinical trial results. What justifies serious consideration of fisetin is the combination of: a compelling and consistent animal evidence base (including lifespan extension in aged mice), a well-characterized mechanism (senolytic clearance of cells whose accumulation is directly linked to aging pathology), an emerging but still incomplete human clinical trial program, and a favorable safety profile at commonly used doses. For people who accept the uncertainties in the current evidence and are comfortable with acting on the best available science rather than waiting for definitive human proof, fisetin is a reasonable inclusion in a longevity stack. For those who want robust human clinical proof before supplementing, waiting for AFFIRM results and the larger trials following is the more conservative approach.